Smith+Nephew has launched the CENTRIO Platelet-Rich-Plasma (PRP) System in the United States. The product is a biodynamic hematogel derived from a patient’s own platelets and plasma that, once applied, may help the natural healing process by maintaining a moist wound environment. 

Smith+Nephew has entered into an exclusive private label distribution agreement with biodynamic therapies developer Nuo Therapeutics Inc. to market the CENTRIO PRP System in the United States.

CENTRIO PRP System can help manage chronic exuding wounds including but not limited to diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers, and tunnelling wounds. A National Coverage Determination (NCD) that took effect in April 2021 provides CMS reimbursement for autologous PRP in treating chronic non-healing wounds in diabetic patients when prepared by devices intended to manage exuding cutaneous wounds, such as diabetic ulcers.¹ The CENTRIO PRP System is designed for point-of-care use in both hospital and physician office settings and the gel can be tailored to fit wound shape, depth, and stage with a single blood draw. CENTRIO PRP System has demonstrated efficacy in two randomized, controlled clinical trials,^2,3 making it a strong fit in Smith+Nephew’s portfolio.

“CENTRIO PRP System sits perfectly alongside our portfolio of skin substitutes to offer a portfolio of biological solutions that augment healing outcomes backed by extensive clinical evidence,” said Vincent Fath, senior vice president of U.S. Advanced Wound Management at Smith+Nephew. “We are pleased to be able to expand access to this exciting and highly differentiated technology to help ease the burden of living with hard to heal wounds.”

The CENTRIO PRP System is premiering at the Symposium on Advanced Wound Care (SAWC) Fall Conference in Las Vegas (Sept. 3-6). 

Smith+Nephew is a portfolio medical technology business focused on repairing, regenerating, and replacing soft and hard tissue. Its 17,000 employees make a difference to patients’ lives through the company’s product portfolio, and the invention and application of new technologies across three global business units—Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Founded in Hull, UK, in 1856, Smith+Nephew operates in roughly 100 countries, and generated $5.8 billion in 2024 sales. Smith+Nephew is a constituent of the FTSE100.

References
¹ NCD – Blood-Derived Products for Chronic Non-Healing Wounds (270.3)
² Gude, Warren MD; Hagan, Daniel DPM, DABPS; Abood, Ferial MD; Clausen, Peter PhD. Aurix Gel Is an Effective Intervention for Chronic Diabetic Foot Ulcers: A Pragmatic Randomized Controlled Trial. Advances in Skin & Wound Care 32(9):p 416-426, September 2019. | DOI: 10.1097/01.ASW.0000577140.19174.9e
³ Driver VR, Hanft J, Fylling CP, Beriou JM; Autologel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006 Jun;52(6):68-70, 72, 74 passim. PMID: 16799184.